Showing results (21-30 of 28) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Molecular Cancer Therapeutics|April 26, 2015
Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody TherapeuticJeffrey D Kearns, Raghida Bukhalid, Mark Sevecka, et al.Immunity|February 22, 2011
Nuclear export of the NF-κB inhibitor IκBα is required for proper B cell and secondary lymphoid tissue formationShelly M Wuerzberger-Davis, Yuhong Chen, David T Yang, et al.Journal of Pharmacokinetics and Pharmacodynamics|August 11, 2022
Current practices for QSP model assessment: an IQ consortium surveyJason R Chan, Richard Allen, Britton Boras, et al.Proceedings of the National Academy of Sciences of the United States of America|March 23, 2019
MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAMJessica B Casaletto, Melissa L Geddie, Adnan O Abu-Yousif, et al.Science Translational Medicine|February 1, 2023
Anti-brolucizumab immune response as one prerequisite for rare retinal vasculitis/retinal vascular occlusion adverse eventsAnette C Karle, Matthias B Wrobel, Stephan Koepke, et al.Science Translational Medicine|February 1, 2023
A root cause analysis to identify the mechanistic drivers of immunogenicity against the anti-VEGF biotherapeutic brolucizumabJeffrey D Kearns, Paul Wassmann, Ufuk Olgac, et al.Elife|October 12, 2021
USP28 deletion and small-molecule inhibition destabilizes c-MYC and elicits regression of squamous cell lung carcinomaE Josue Ruiz, Adan Pinto-Fernandez, Andrew P Turnbull, et al.Cancer Discovery|April 11, 2022
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12CAndreas Weiss, Edwige Lorthiois, Louise Barys, et al.Pageof 3